Alimera Sciences

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Alimera Sciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 4 completed later-stage tilt upper quartile by trial count

Alimera Sciences: 8 sponsored US clinical trials, none currently recruiting.

Alimera Sciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Uveitis, Posterior, with 1 trials.

Upper-quartile sponsor footprint

Alimera Sciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 4

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
ACTIVE NOT RECRUITING Phase 4

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

NCT04469595
COMPLETED Phase 4

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
COMPLETED Phase 3

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
TERMINATED Phase 2

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
TERMINATED Phase 2

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318
COMPLETED Phase 3

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

NCT00344968
COMPLETED Phase 3

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 3
Phase 4 3

Therapeutic Areas

Uveitis, Posterior 1
Diabetic Macular Edema 1

How the Alimera Sciences archive is shaped

8 indexed studies, none listed as recruiting (0% open); 4 completed (50%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Uveitis, Posterior (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Alimera Sciences: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Alimera SciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alimera Sciences page

8 registered trials is a research-attention snapshot, not an endorsement of Alimera Sciences or any single study.

  • None of Alimera Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Uveitis, Posterior is the condition Alimera Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Uveitis, Posterior trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alimera Sciences pipeline card: 8 registered trials from official public datasets.Report a data error.